NCT04607954 2026-03-31Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerMayo ClinicPhase 2 Active not recruiting29 enrolled
NCT05578326 2026-03-30Study of Trilaciclib and LurbinectidinUNC Lineberger Comprehensive Cancer CenterPhase 2 Recruiting30 enrolled
NCT06228066 2026-03-23Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)National Institutes of Health Clinical Center (CC)Phase 2 Recruiting45 enrolled
NCT07459634 2026-03-10A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCJazz PharmaceuticalsPhase 2 Not yet recruiting50 enrolled